Colón reject Forneris bid: what other options do Racing have?
Colón reject Forneris bid: what other options do Racing have?
These days, Racing Club is focused on the transfer market, and has already set its sights on one of its targets: Alan Forneris.
The young midfielder who plays for Colón has been the main target at the Academy to strengthen the squad for the second half of the season.
Advertisement
Racing has already made an offer but Colón rejected it as insufficient.
New offer or other options?
According to information from Racing de Alma, the Academy offered one million dollars for Alan Forneris, intending to include in the negotiation the card of Germán Conti, who has no place in Gustavo Costas' team.
While Conti is also wanted by Belgrano, Colón is not interested in the central defender, and rejected Racing's million-dollar offer.
The Sabalero demands two million for Fornaris, and also wants to keep 20% of his card. This week it will be decided whether Racing meets Colón's demands to add Forneris, or changes its strategy and looks for other names to strengthen the midfield.
Advertisement
In this regard, other players that the board led by Diego Milito would have in mind have already been leaked.
The first is Lautaro López, a 20-year-old midfielder who plays for Montevideo City Torque in Uruguay, and who has experience in the Argentina Under-20 team.
Another option is Facundo Di Biasi, a 19-year-old central midfielder who plays for Gimnasia y Esgrima in La Plata.
This article was translated into English by Artificial Intelligence. You can read the original version in 🇪🇸 here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
5 hours ago
- Medscape
Inexpensive HIV Med Improves Vision in Diabetic Eye Disease
Oral lamivudine, an inflammasome inhibitor originally approved for suppressing HIV, was a relatively safe and effective treatment for improving visual acuity in adults with center-involving diabetic macular edema, a serious complication of diabetic retinopathy. METHODOLOGY: Researchers conducted a clinical trial to assess the effectiveness of oral lamivudine vs placebo in improving visual acuity in 24 adults (mean age, 62.7 years; 55% women) with type 2 diabetes and center-involving diabetic macular edema from a tertiary center in São Paulo, Brazil. Best-corrected visual acuity was less than 69 letters in this cohort. The participants were randomly assigned to receive either oral lamivudine (150 mg twice daily; 10 participants; 16 eyes) or placebo (14 participants; 21 eyes) for 8 weeks, with intravitreous bevacizumab (1.25 mg) administered at week 4. Primary outcomes were the mean changes in best-corrected visual acuity from baseline to weeks 4 and 8, and secondary outcomes included changes in retinal thickness and adverse events. Outcomes in the lamivudine group were compared with those in a historical cohort of individuals who received aflibercept, bevacizumab, or ranibizumab. TAKEAWAY: Participants who received lamivudine experienced a significant improvement in visual acuity as early as week 4, with a mean gain of 9.8 letters on the eye chart, whereas those on placebo had a mean loss of 1.8 letters ( P < .001) ; 94% of eyes in the lamivudine group showed an improvement in best-corrected visual acuity compared with just 24% in the placebo group. < .001) ; 94% of eyes in the lamivudine group showed an improvement in best-corrected visual acuity compared with just 24% in the placebo group. Following injection of bevacizumab at week 4, patients in the lamivudine group showed greater improvement in visual acuity than those who received placebo (16.9 vs 5.3 letters; P < .001) at week 8. < .001) at week 8. When compared with drugs in the historical cohort, lamivudine was at least as effective as aflibercept and more effective than bevacizumab or ranibizumab. No significant differences were observed in retinal thickness or adverse events between the lamivudine and placebo groups; no serious systemic adverse events such as lactic acidosis or hepatic or renal toxicity were reported during the study period. IN PRACTICE: Continual intravitreous administration of anti–vascular endothelial growth factor drugs, 'which requires frequent visits to doctors' offices, imposes a substantial burden on patients and healthcare systems,' the researchers reported. 'Repurposing existing drugs such as lamivudine enables potentially immediate translation to practice and could obviate the aforementioned challenges by reducing medication costs and eliminating intravitreous injection costs. Such an oral medication would also avoid the potentially blinding complications of intravitreous injections.' 'These findings open the door to a more accessible and less invasive treatment approach for DME [diabetic macular edema], with the potential to benefit millions of patients globally,' they added. SOURCE: This study was led by Felipe Pereira of the Universidade Federal de São Paulo, São Paulo, Brazil. It was published online on May 27, 2025, in Med . LIMITATIONS: The relatively small number of participants was a major limitation. The 8-week duration of the study — imposed because of safety concerns over lamivudine's potential toxicity — precluded assessment of its long-term efficacy and safety. This study took place at a single center in Brazil and involved participants whose characteristics differed from those from the historical cohort who were based in the United States. DISCLOSURES: This study received support from the Universidade Federal de São Paulo, Latinofarma, the National Institutes of Health, and other sources. Some authors declared receiving consultancy fees, were named as inventors on matter-related patent applications, served as scientific consultants, and had other ties with many sources, including the funding agencies.
Yahoo
7 hours ago
- Yahoo
Davide Frattesi returns on Roma's radar
Davide Frattesi is back on Roma's radar. The Inter midfielder, protagonist of an up-and-down season, could leave Milan in the summer. According to Leggo, the Giallorossi are ready to attempt a new approach in view of the summer transfer market. Advertisement Two elements are crucial in this scenario: the player's desire to return to the capital and the imminent arrival of Gian Piero Gasperini, who has already identified Frattesi as an ideal profile to replicate in Rome the role played by Ederson in Atalanta. The competition remains strong, with Napoli also involved in the race for Frattesi, but Roma will move decisively.
Yahoo
7 hours ago
- Yahoo
Hawks & Spartans X 2 Titles
PERU, NY – The 2025 Section 7 Track & Field championships would crown 4 teams champs this year for the first time. The track & field team finals would be split up into two classifications, for each of the boys and girls divisions. The host school Peru, would beat out Beekmantown and Plattsburgh High in Class 'B' for both the boys and girls titles. While it was also a sweep for Saranac in Class 'C', again for the boys and girls once again. Highlights from the day including individual winners, team winners, and hear from the champions, in the video above. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
